This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This study is being performed by the Pediatric Heart Network and is sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health. Approximately 14 patients will take part in this study per year at Cincinnati Children's Hospital Medical Center and it is planned that a total of 230 patients will be enrolled from all of the hospitals. Enalapril (Vasotec ) belongs to a class of medications known as angiotensin converting enzyme (ACE) inhibitors. It is used to treat high blood pressure and congestive heart failure in adults and children. ACE inhibitors dilate the vessels that take blood from the heart to the body making it easier for blood to flow through these vessels. This vasodilation reduces the work of the heart in many patients by decreasing how hard it has to squeeze to eject blood. Although enalapril is well tolerated in children, there is only limited data demonstrating the effectiveness of enalapril in children with heart problems, especially in infants with single ventricle hearts. The purpose of this research study is to find out whether enalapril improves heart function and growth in infants with single ventricle hearts during the first year of life.
Showing the most recent 10 out of 502 publications
